In ₹ Crore except Per Share Latest Annual	GLAND FY26	DIVISLAB FY26	AUROPHARMA FY26	PPLPHARMA FY26	Peer Average
Valuation — at last close
P/E	49.31×	99.89×	◆ 27.51×	—	63.70× -23%
P/B	4.89×	15.28×	◆ 2.54×	3.75×	7.19× -32%
EV/EBITDA	29.17×	73.43×	◆ 13.65×	37.73×	41.60× -30%
Market Cap	₹50,655 Cr	₹2.56L Cr	₹96,407 Cr	₹30,628 Cr	₹1.28L Cr -60%
Growth
Revenue CAGR 3Y	◆ 21.06%	10.78%	10.63%	7.79%	9.73% +116%
Revenue CAGR 5Y	◆ 13.18%	8.67%	6.32%	—	7.50% +76%
Net Income CAGR 3Y	9.57%	12.09%	◆ 22.03%	—	17.06% -44%
Revenue YoY (latest Q)	19.57%	27.80%	16.30%	◆ 28.05%	24.05% -19%
Net Income YoY (latest Q)	47.09%	65.50%	25.22%	◆ 105.07%	65.26% -28%
Profitability
EBITDA Margin	25.34%	◆ 32.59%	20.34%	10.39%	21.11% +20%
Net Income Margin	15.98%	◆ 24.32%	10.41%	-3.68%	10.35% +54%
Return on Common Equity	10.53%	◆ 16.19%	9.94%	-4.00%	7.38% +43%
Return on Capital Employed	11.73%	◆ 17.80%	13.41%	0.72%	10.64% +10%
Return on Assets	8.66%	◆ 13.89%	6.47%	-1.94%	6.14% +41%
Credit & Quality
Total Debt/Equity	0.02×	◆ 0.00×	0.20×	0.67×	0.29× -93%
Interest Coverage	36.24×	◆ 129.48×	13.20×	0.27×	47.65× -24%
Scale — latest FY
Revenue / Total Income	₹6,431 Cr	₹10,560 Cr	₹33,653 Cr	₹8,869 Cr	₹17,694 Cr -64%
Net Income	₹1,027 Cr	₹2,568 Cr	₹3,503 Cr	−₹326 Cr	₹1,915 Cr -46%
Total Assets	₹12,511 Cr	₹20,033 Cr	₹58,502 Cr	₹17,965 Cr	₹32,167 Cr -61%
EPS	₹62.35	₹96.75	₹60.34	₹-2.46	₹51.54 +21%
Book Value per Share	₹628.67	₹632.49	₹652.39	₹61.5	₹448.79 +40%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.